<?xml version="1.0" encoding="UTF-8"?>
<table-wrap position="float" id="tbl3">
 <label>Table 3</label>
 <caption>
  <p>Based on the available evidence so far (including 
   <italic>in vitro</italic>, 
   <italic>ex vivo</italic> and 
   <italic>in vivo</italic> studies – both experimental and two human studies) and considering the benefit-risk ratio as well as the low cost of chloroquine and hydroxychloroquine in Indian context, we propose the following regime, until more evidence is available -
  </p>
 </caption>
 <alt-text id="alttext0020">Table 3</alt-text>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>Timing of intervention</th>
    <th>Proposed</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td align="left">Chemoprophylaxis</td>
    <td align="left">
     <list list-type="simple" id="ulist0025">
      <list-item id="u0045">
       <label>•</label>
       <p id="p0150">No conclusive evidence so far; however, chloroquine or HCQ could be researched as a prophylactic agent in endemic areas. Recent guidelines from Indian Council of Medical Research recommend it as prophylactic agent (see reference 42 for indication and dose)</p>
      </list-item>
      <list-item id="u0050">
       <label>•</label>
       <p id="p0155">Note: HCQ can be used as an adjunct to control glycemia in adult patients with type 2 diabetes (approved for treatment in India). However, role of such adjunctive treatment for testing its potential role as a prophylaxis of COVID-19 in diabetes, has not been researched but could be attempted (in view of above) considering a higher mortality in patients with diabetes, as compared to non-diabetic subjects with COVID-19.</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left">Confirmed COVID-19</td>
    <td align="left">A. Chloroquine phosphate: 
     <sup>@$</sup>
     <break/>1. COVID-19 URTI: 500 mg BID for 5 days.
     <break/>2. COVID-19 LRTI: 500 mg BID for 10 days.
     <break/>B. Hydroxychloroquine: 
     <sup>@$</sup>
     <break/>Loading dose: 400 mg BID day 1, then
     <break/>Maintenance dose: 200 mg BID for 5–10 days.
     <break/>C. Monitor and watch for side effects∗
    </td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <fn>
   <p>@ watch for hypoglycemia in diabetes especially with concurrent use of lopinavir/ritonavir, $ should not be used concurrently with lopinavir/ritonavir and remdisivir due to increased QTc prolongation, ∗ complete blood count, renal, hepatic profile and ECG – watch for QTc prolongation, URTI- upper respiratory tract infection, LRTI- lower respiratory tract infection, HCQ-hydroxychloroquine, BID – twice daily.</p>
  </fn>
 </table-wrap-foot>
</table-wrap>
